GnRH antagonists

Clinical Obstetrics and Gynecology

Volumn 46, Issue 2, 2003, Pages 254-264

  Chabbert Buffet, Nathalie ^a,d   Olivennes, François ^b   Bouchard, Philippe ^c  

^a HÔPITAL TENON   (France)

^b Hôpital Cochin APHP ^*  (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d Physiopathologie de l'Implantation et du Développement   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABARELIX; CETRORELIX; DANAZOL; GANIRELIX; GESTAGEN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; ITURELIX; ORAL CONTRACEPTIVE AGENT; PYRIDINE DERIVATIVE; QUINOLINE DERIVATIVE; RECOMBINANT FOLLITROPIN; TEVERELIX; TRIPTORELIN;

CLINICAL PROTOCOL; CLINICAL TRIAL; CONTRACEPTION; COST CONTROL; DOSE CALCULATION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; ENDOMETRIOSIS; FERTILITY; FERTILIZATION IN VITRO; HUMAN; LONG TERM CARE; LUTEINIZING HORMONE RELEASE; META ANALYSIS; OVARY FUNCTION; OVARY HYPERSTIMULATION; OVULATION; PLASMA HALF LIFE; PRECOCIOUS PUBERTY; PREGNANCY RATE; RECEPTOR DOWN REGULATION; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; TREATMENT OUTCOME; UTERINE ARTERY EMBOLIZATION;

FEMALE; FERTILITY AGENTS; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; OVULATION INDUCTION; PREGNANCY;

EID: 0038826226     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003081-200306000-00007     Document Type: Review

References (50)

1. Al-Inany H, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev. 2001;4.
2. Baba Y, et al. Structure of the porcine LH and FSH releasing hormone. II. Confirmation of the proposed structure by conventional sequential analysis. Biochem Biophys Res Commun. 1971;44:459-463.
3. Cusan L, et al. Inhibitory effects of long-term treatment with a LHRH agonist on the pituitary-gonadal axis in male and female rats. Endocrinology. 1979;104:1369-1376.
4. Bouchard P, Garcia E. Comparison of the mechanisms of action of LHRH analogs and steroids in the treatment of endometriosis. Contrib Gynecol Obstet. 1987;16:260-265.
5. Bouchard P, Wolf JP, Hajri S. Inhibition of ovulation: comparison between the mechanism of action of steroids and GnRH analogues. Hum Reprod. 1988;3:503-506.
6. Karten MJ, Rivier JE. Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective. Endocr Rev. 1986;7:44-66.
7. Gordon K, et al. Evolving role of GnRH antagonists. Trends in Endocrinol Metab. 1992;3:259-263.
8. Felberbaum RE, Ludwig M, Diedrich K. Clinical application of GnRH-antagonists. Mol Cell Endocrinol. 2000;166:9-14.
9. Sundaram K, Didolkar A, Thau R, et al. Antagonists of luteinizing hormone releasing hormone bind to rat mast cells and induce histamine release. Agents Actions. 1988;25:307-313.
10. Felberbaum R, Ludwig M, Diedrich K. Agonists and Antagonists, Formulation and Indication in GnRH Analogues. Philadelpia: WB Saunders; 2001.
11. Gillies PS, Faulds D, Balfour JA, Perry CM. Ganirelix. Drugs. 2000;59:107-113.
12. Reissmann T, Schally AV, Bouchard P, et al. The LHRH antagonist cetrorelix: a review. Hum Reprod Update. 2000;6:322-331.
13. Blithe DL. Applications for GnRH antagonists. Trends Endocrinol Metab. 2001;12:238-240.
14. Ditkoff EC, Cassidenti DL, Paulson RJ, et al. The gonadotropin-releasing hormone antagonist (Nal-Glu) acutely blocks the luteinizing hormone surge but allows for resumption of folliculogenesis in normal women. Am J Obstet Gynecol. 1991;165:1811-1817.
15. Leroy I, d'Acremont M, Brailly-Tabard S, et al. A single injection of a gonadotropin-releasing hormone (GnRH) antagonist (Cetrorelix) postpones the luteinizing hormone (LH) surge: further evidence for the role of GnRH during the LH surge. Fertil Steril. 1994;62:461-467.
16. Christin-Maitre S, Olivennes F, Dubourdieu S, et al. Effect of gonadotrophin-releasing hormone (GnRH) antagonist during the LH surge in normal women and during controlled ovarian hyperstimulation. Clin Endocrinol (Oxf). 2000;52:721-726.
17. Dubourdieu S, Charbonnel B, D'Acremont MF, et al. Effect of administration of a gonadotropin-releasing hormone (GnRH) antagonist (Nal-Glu) during the periovulatory period: the luteinizing hormone surge requires secretion of GnRH. J Clin Endocrinol Metab. 1994;78:343-347.
18. Lahlou N, Delivet S, Bardin CW, et al. Changes in gonadotropin and alpha-subunit secretion after a single administration of gonadotropin-releasing hormone antagonist in adult males. Fertil Steril. 1990;53:898-905.
19. Diedrich K, Frydman R, Devroey P, et al. Comment on the debate article: embryo implantation: the Rubicon for GnRH antagonists. Hum Reprod. 2001;16:1305-1306.
20. Diedrich K, Ludwig M, Felberbaum RE. The role of gonadotropin-releasing hormone antagonists in in vitro fertilization. Semin Reprod Med. 2001;19:213-220.
21. Frydman R, Cornel C, de Ziegler D, et al. Spontaneous luteinizing hormone surges can be reliably prevented by the timely administration of a gonadotrophin releasing hormone antagonist (Nal-Glu) during the late follicular phase. Hum Reprod. 1992;7:930-933.
22. Bouchard P, Fauser BC. Gonadotropin-releasing hormone antagonist: new tools versus old habits. Fertil Steril. 2000;73:18-20.
23. Olivennes F, Belaisch-Allart J, Emperaire JC, et al. Prospective, randomized, controlled study of in vitro fertilization/embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril. 2000;73:314-320.
24. Olivennes F, Cunha-Filho JS, Fanchin R, et al. The use of GnRH antagonists in ovarian stimulation. Hum Reprod Update. 2002;8:279-290.
25. Olivennes F, Fanchin R, Bouchard P, et al. Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day 8 of in-vitro fertilization cycles: a pilot study. Hum Reprod. 1995;10:1382-1386.
26. Olivennes F, Alvarez S, Bouchard P, et al. The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose-finding study of 3 versus 2 mg. Hum Reprod. 1998;13:2411-2414.
27. Albano C, Felberbaum R, Smitz J. Ovarian stimulation with HMG: a prospective randomized phase III European study comparing the luteinizing hormone releasing hormone (LHRH) antagonist cetrorelix and the LHRH-agonist buserelin. Hum Reprod. 2000;15:526-531.
28. The European Orgalutran Study Group. Treatment with gonadotropin releasing hormone antagonist cetrorelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled randomized, multicenter trial. Hum Reprod. 2000;15:1490-1498.
29. The North American Ganirelix Study Group. Efficacy and safety of ganirelix acetate vs. leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril. 2001;75:38-45.
30. European And Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod. 2001;16:644-651.
31. Al-Inany H, Aboulghar M. GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod. 2002;17:874-885.
32. de Jong D, Macklon NS, Fauser BC. A pilot study involving minimal ovarian stimulation for in vitro fertilization: extending the follicle-stimulating hormone window combined with the gonadotropin-releasing hormone antagonist cetrorelix. Fertil Steril. 2000;73:1051-1054.
33. Hohmann FP, Macklon NS, Fauser BC. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist co-treatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. J Clin Endocrinol Metab. 2003;88:166-173.
34. Rongieres-Bertrand C, Olivennes F, Righini C, et al. Revival of the natural cycles in invitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation. Hum Reprod. 1999;14:683-688.
35. Olivennes F, Fanchin R, Bouchard P, et al. Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH antagonist. Fertil Steril. 1996;66:151-153.
36. Lewit N, Kol S, Manor D, Itskovitz-Eldor J. Comparison of gonadotrophin-releasing hormone analogues and human chorionic gonadotrophin for the induction of ovulation and prevention of ovarian hyperstimulation syndrome: a case-control study. Hum Reprod. 1996;11:1399-1402.
37. Beckers NGM. Comparison of the nonsupplemented luteal phase characteristics after recombinant (r)hCG, rLH on GnRH agonist for oocyte maturation in IVF. Hum Reprod. 2002:157.
38. Tavaniotou A, Albano C, Smitz J, Devroey P. Impact of ovarian stimulation on corpus luteum function and embryonic implantation. J Reprod Immunol. 2002;55:123-130.
39. Kupker W, Felberbaum R, Krapp M, et al. Use of GnRH antagonists in the treatment of endometriosis. Reprod Biomed Online. 2002;5:12-16.
40. Felberbaum R, Kupker W, Diedrich K. Will GnRH antagonists assist in the treatment of benign gynaecological diseases? Reprod Biomed Online. 2002;5:68-72.
41. Sklar CA RS, Blumberg D, Oberfield SE, et al. Suppression of the pituitary-gonadal axis in children with central precocious puberty: effects on growth, growth hormone, insulin-like growth factor-I, and prolactin secretion. J Clin Endocrinol Metab. 1991;73:734-738.
42. Anderson RA. Hormonal contraception in the male. Br Med Bull. 2000;56:717-728.
43. Behre HM, Kliesch S, Lemcke B, et al. Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone. Hum Reprod. 2001;16:2570-2577.
44. Kolibianakis E, Bourgain C, Albano C, et al. Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pickup. Fertil Steril. 2002;78:1025-1029.
45. Kol S. Embryo implantation and GnRH antagonists: GnRH antagonists in ART: lower embryo implantation? Hum Reprod. 2000;15:1881-1882.
46. Ludwig M, Riethmuller-Winzen H, Felberbaum RE, et al. Health of 227 children born after controlled ovarian stimulation for in vitro fertilization using the luteinizing hormone-releasing hormone antagonist cetrorelix. Fertil Steril. 2001;75:18-22.
47. Olivennes F, Mannaerts B, Struijs M, et al. Perinatal outcome of pregnancy after GnRH antagonist (ganirelix) treatment during ovarian stimulation for conventional IVF or ICSI: a preliminary report. Hum Reprod. 2001;16:1588-1591.
48. Young JR, Huang SX, Chen I, et al. Quinolones as gonadotropin releasing hormone (GnRH) antagonists: simultaneous optimization of the C(3)-aryl and C(6)-substituents. Bioorg Med Chem Lett. 2000;10:1723-1727.
49. Herbst KL, Anawalt BD, Amory JK, Bremner WJ. Acyline: the first study in humans of a potent, new gonadotropin-releasing hormone antagonist. J Clin Endocrinol Metab. 2002;87:3215-3220.
50. Sasaki S, Cho N, Nara Y, et al. Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: a highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor. J Med Chem. 2003;46:113-124.